NCT00570726已完成1 期
Effect of Needle Bleb Revision With Ranibizumab as a Primary Intervention in a Failing Bleb Following Trabeculectomy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 6
- 试验地点
- 1
研究概览
简要总结
This study was designed to evaluate the efficacy and safety in the use of Ranibizumab, an effective vascular endothelial growth factor (VGEF) inhibitor, in treating patients with a failing bleb, characterized by increased fibrosis and vascularization of the conjuctiva, following trabeculectomy. Six subjects from one site will be enrolled in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to provide written informed consent and comply with study assessments for the full duration of the study
- •Age > 40 years
- •Patients with Open-angle Glaucoma who have had trabeculectomy
- •Patients determined to have failing bleb with presence of superficial bleb vascularity and IOP increase on 3 successive visits without topical medication
- •Patients whose intraocular pressure (IOP) is above goal IOP after suture lysis and digital compression have been attempted
排除标准
- •Pregnancy (positive pregnancy test) or lactation.
- •Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.
- •Current infection or inflammation in either eye
- •Any abnormality preventing reliable applanation tonometry in either eye
- •Other non-glaucomatous disease affecting visual field, (pituitary lesions, demyelinating disease, congenital optic nerve anomaly, prior retinal and optic nerve vascular occlusive disease, retinal dystrophy and degeneration, diabetes and HIV and AIDS infection)
- •Strabismus, nystagmus, monocular patient
- •Prior enrollment in the study
- •Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
- •Participation in another simultaneous medical investigation or trial
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular DegenerationVisual AcuityMacular DegenerationNCT00813891McGill University Health Centre/Research Institute of the McGill University Health Centre180
终止
不适用
Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma SurgeryGlaucomaNCT00644280University of California, San Francisco11
已完成
1 期
Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous ChorioretinopathyChronic Central Serous ChorioretinopathyNCT01325181Jang Won Heo34
已完成
3 期
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular EdemaDiabetic Macular EdemaNCT01627249Jaeb Center for Health Research660
已完成
1 期
Effect of Ranibizumab on Malignant Conjunctival NeoplasiaConjunctival NeoplasmsNCT00456495The New York Eye Cancer Center5